Skip to main content
SpringerLink
Log in

The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The presence of JAK2 V617F is associated with an inherited JAK2 46/1 haplotype, a risk factor for myeloproliferative neoplasms (MPN) in Caucasian populations. Whether the JAK2 46/1 haplotype is also a risk factor in the Chinese population is unknown. We assessed for the JAK2 46/1 haplotype and JAK2 V617F mutation in 225 MPN patients and 226 controls using a tagged SNP rs12340895. The allele frequencies of the JAK2 46/1 haplotype were distinct among different subtypes of MPN patients. The allele frequency was significantly higher in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) than that in controls, with PV patients having the highest allele frequency (0.58, P = 6.00E−15). The distribution of rs12340895 genotypes in the JAK2 V617F mutated MPN patients was significantly different from that in controls (P = 1.67E−15). The percentage of GG genotype in controls was 2.2 %, but 31.0 % in JAK2 V617F-positive MPN patients. All the PV, ET, and PMF patients with the GG genotype also exhibited the V617F mutation. Compared to that of controls, the difference in genotype distribution in PV patients was the most significant (P = 4.83E−21), followed by ET (P = 2.07E−05) and PMF (P = 1.99E−04). Our results suggest that the JAK2 46/1 haplotype is a risk factor for MPN in the Chinese population, and patients with GG genotype in rs12340895 locus are susceptible to JAK2 V617F mutation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Abdel-Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol. 2011;18(2):117–23.

    Article  PubMed  Google Scholar 

  2. Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. BMC Med Genet. 2012;13:6.

    Article  PubMed  CAS  Google Scholar 

  3. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450–4.

    Article  PubMed  CAS  Google Scholar 

  4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8.

    Article  PubMed  CAS  Google Scholar 

  5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97.

    Article  PubMed  CAS  Google Scholar 

  6. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61.

    PubMed  CAS  Google Scholar 

  7. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573–82.

    Article  PubMed  CAS  Google Scholar 

  8. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199–204.

    Article  PubMed  CAS  Google Scholar 

  9. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455–9.

    Article  PubMed  CAS  Google Scholar 

  10. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446–9.

    Article  PubMed  CAS  Google Scholar 

  11. Wu Z, Yuan H, Zhang X, Liu W, Xu J, Zhang W, et al. Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. PLoS ONE. 2011;6(10):e26534.

    Article  PubMed  CAS  Google Scholar 

  12. Vossen RH, van Duijn M, Daha MR, den Dunnen JT, Roos A. High-throughput genotyping of mannose-binding lectin variants using high-resolution DNA-melting analysis. Hum Mutat. 2010;31(4):E1286–93.

    Article  PubMed  CAS  Google Scholar 

  13. Liu SM, Xu FX, Shen F, Xie Y. Rapid genotyping of APOA5 -1131T>C polymorphism using high resolution melting analysis with unlabeled probes. Gene. 2012;498(2):276–9.

    Google Scholar 

  14. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19(3):225–68.

    Article  PubMed  CAS  Google Scholar 

  15. Reddy MM, Deshpande A, Sattler M. Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin Ther Targets. 2012;16(3):313–24.

    Article  PubMed  CAS  Google Scholar 

  16. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–87.

    Article  PubMed  CAS  Google Scholar 

  17. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia. 2010;24(1):110–4.

    Article  PubMed  CAS  Google Scholar 

  18. Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica. 2011;96(11):1575–9.

    Article  PubMed  CAS  Google Scholar 

  19. Zhang X, Gu X, Liu S, Ma W, Guan M. Detection of JAK2 V617F mutation by real-time PCR. Clin J Lab Med (Chinese). 2009;32(5):583–6.

    Google Scholar 

  20. Alvarez-Larran A, Angona A, Martinez-Aviles L, Bellosillo B, Besses C. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms. Leuk Res. 2012;36(3):324–6.

    Article  PubMed  CAS  Google Scholar 

  21. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21(9):1952–9.

    Article  PubMed  CAS  Google Scholar 

  22. Andrikovics H, Nahajevszky S, Koszarska M, Meggyesi N, Bors A, Halm G, et al. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia. Leukemia. 2010;24(10):1809–13.

    Article  PubMed  CAS  Google Scholar 

  23. Guglielmelli P, Biamonte F, Spolverini A, Pieri L, Isgro A, Antonioli E, et al. Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia. 2010;24(8):1533–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from the National Clinical Key Subject, and two grants from the Shanghai Science and Technology Commission (Grant No. 11JC1401800 and No. 10411950200) and Scientific Research Foundation for New teacher of Fudan University (JJF151002).

Conflict of interest

The authors declare that they have no conflict of interests.

Author information

Authors and Affiliations

  1. Department of Central Laboratory, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Central Urumqi Road, Shanghai, 200040, People’s Republic of China

    Xinju Zhang & Ming Guan

  2. Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Central Urumqi Road, Shanghai, 200040, People’s Republic of China

    Tingting Hu, Zhiyuan Wu, Zhihua Kang, Weiwei Liu & Ming Guan

Authors
  1. Xinju Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tingting Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhiyuan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhihua Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weiwei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ming Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Weiwei Liu or Ming Guan.

Additional information

X. Zhang and T. Hu equally contributed to this study.

About this article

Cite this article

Zhang, X., Hu, T., Wu, Z. et al. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients. Int J Hematol 96, 611–616 (2012). https://doi.org/10.1007/s12185-012-1169-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1169-8

Keywords

Search

Navigation